<?xml version="1.0" encoding="UTF-8"?><abstracts-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:dn="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:ait="http://www.elsevier.com/xml/ani/ait" xmlns:ce="http://www.elsevier.com/xml/ani/common" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/abstract/scopus_id/85139981269</prism:url><dc:identifier>SCOPUS_ID:85139981269</dc:identifier><eid>2-s2.0-85139981269</eid><pubmed-id>36232909</pubmed-id><prism:doi>10.3390/ijms231911610</prism:doi><article-number>11610</article-number><dc:title>The Interplay between GSK3β and Tau Ser262 Phosphorylation during the Progression of Tau Pathology</dc:title><prism:aggregationType>Journal</prism:aggregationType><srctype>j</srctype><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><citedby-count>0</citedby-count><prism:publicationName>International Journal of Molecular Sciences</prism:publicationName><dc:publisher>MDPI</dc:publisher><source-id>25879</source-id><prism:issn>14220067 16616596</prism:issn><prism:volume>23</prism:volume><prism:issueIdentifier>19</prism:issueIdentifier><prism:coverDate>2022-10-01</prism:coverDate><openaccess>1</openaccess><openaccessFlag>true</openaccessFlag><dc:creator><author seq="1" auid="56724920100"><ce:initials>L.</ce:initials><ce:indexed-name>Song L.</ce:indexed-name><ce:surname>Song</ce:surname><ce:given-name>Liqing</ce:given-name><preferred-name><ce:initials>L.</ce:initials><ce:indexed-name>Song L.</ce:indexed-name><ce:surname>Song</ce:surname><ce:given-name>Liqing</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/56724920100</author-url><affiliation id="60027950" href="https://api.elsevier.com/content/affiliation/affiliation_id/60027950"/></author></dc:creator><dc:description><abstract xmlns="" original="y" xml:lang="eng"><publishercopyright>© 2022 by the authors.</publishercopyright><ce:para>Tau hyperphosphorylation has been linked directly to the formation of toxic neurofibrillary tangles (NFTs) in tauopathies, however, prior to NFT formation, the sequence of pathological events involving tau phosphorylation remains unclear. Here, the effect of glycogen synthase kinase 3β (GSK3β) on tau pathology was examined independently for each step of transcellular propagation; namely, tau intracellular aggregation, release, cellular uptake and seeding activity. We find that overexpression of GSK3β-induced phosphorylated 0N4R tau led to a higher level of tau oligomerization in SH-SY5Y neuroblastoma cells than wild type 0N4R, as determined by several orthogonal assays. Interestingly, the presence of GSK3β also enhanced tau release. Further, we demonstrated that cells endocytosed more monomeric tau protein when pre-phosphorylated by GSK3β. Using an extracellular vesicle (EVs)-assisted tau neuronal delivery system, we show that exosomal GSK3β-phosphorylated tau, when added to differentiated SH-SY5Y cells, induced more efficient tau transfer, showing much higher total tau levels and increased tau aggregate formation as compared to wild type exosomal tau. The role of a primary tau phosphorylation site targeted by microtubule-affinity regulating kinases (MARKs), Ser262, was tested by pseudo-phosphorylation using site-directed mutagenesis to aspartate (S262D). S262D tau overexpression significantly enhanced tau release and intracellular tau accumulation, which were concurrent with the increase of pathological states of tau, as determined by immunodetection. Importantly, phosphorylation-induced tau accumulation was augmented by co-transfecting S262D tau with GSK3β, suggesting a possible interplay between Ser262 phosphorylation and GSK3β activity in tau pathology. Lastly, we found that pre-treatment of cells with amyloid-β (Aβ) further tau phosphorylation and accumulation when Ser262 pre-phosphorylation was present, suggesting that S262 may be a primary mediator of Aβ-induced tau toxicity. These findings provide a potential therapeutic target for treating tau-related disorders by targeting specific phospho-tau isoforms and further elucidate the GSK3β-mediated pathological seeding mechanisms.</ce:para></abstract></dc:description><link href="https://api.elsevier.com/content/abstract/scopus_id/85139981269" rel="self"/><link href="https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&amp;scp=85139981269&amp;origin=inward" rel="scopus"/><link href="https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&amp;scp=85139981269&amp;origin=inward" rel="scopus-citedby"/></coredata><affiliation id="60027950" href="https://api.elsevier.com/content/affiliation/affiliation_id/60027950"><affilname>Carnegie Mellon University</affilname><affiliation-city>Pittsburgh</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation id="60015112" href="https://api.elsevier.com/content/affiliation/affiliation_id/60015112"><affilname>Tulane University School of Medicine</affilname><affiliation-city>New Orleans</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><authors><author seq="1" auid="56724920100"><ce:initials>L.</ce:initials><ce:indexed-name>Song L.</ce:indexed-name><ce:surname>Song</ce:surname><ce:given-name>Liqing</ce:given-name><preferred-name><ce:initials>L.</ce:initials><ce:indexed-name>Song L.</ce:indexed-name><ce:surname>Song</ce:surname><ce:given-name>Liqing</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/56724920100</author-url><affiliation id="60027950" href="https://api.elsevier.com/content/affiliation/affiliation_id/60027950"/></author><author seq="2" auid="56403167600"><ce:initials>D.E.</ce:initials><ce:indexed-name>Oseid D.E.</ce:indexed-name><ce:surname>Oseid</ce:surname><ce:given-name>Daniel E.</ce:given-name><preferred-name><ce:initials>D.E.</ce:initials><ce:indexed-name>Oseid D.E.</ce:indexed-name><ce:surname>Oseid</ce:surname><ce:given-name>Daniel E.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/56403167600</author-url><affiliation id="60015112" href="https://api.elsevier.com/content/affiliation/affiliation_id/60015112"/></author><author seq="3" auid="57192560042"><ce:initials>E.A.</ce:initials><ce:indexed-name>Wells E.A.</ce:indexed-name><ce:surname>Wells</ce:surname><ce:given-name>Evan A.</ce:given-name><preferred-name><ce:initials>E.A.</ce:initials><ce:indexed-name>Wells E.A.</ce:indexed-name><ce:surname>Wells</ce:surname><ce:given-name>Evan A.</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/57192560042</author-url><affiliation id="60027950" href="https://api.elsevier.com/content/affiliation/affiliation_id/60027950"/></author><author seq="4" auid="7403387058"><ce:initials>A.S.</ce:initials><ce:indexed-name>Robinson A.S.</ce:indexed-name><ce:surname>Robinson</ce:surname><ce:given-name>Anne Skaja</ce:given-name><preferred-name><ce:initials>A.S.</ce:initials><ce:indexed-name>Robinson A.S.</ce:indexed-name><ce:surname>Robinson</ce:surname><ce:given-name>Anne Skaja</ce:given-name></preferred-name><author-url>https://api.elsevier.com/content/author/author_id/7403387058</author-url><affiliation id="60027950" href="https://api.elsevier.com/content/affiliation/affiliation_id/60027950"/></author></authors></abstracts-retrieval-response>